Hampshire, United Kingdom

Melissa A Smith

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Melissa A Smith: Innovator in Pharmacogenomics

Introduction

Melissa A Smith is a prominent inventor based in Hampshire, GB. She has made significant contributions to the field of pharmacogenomics, particularly in the context of drug therapy for immune-mediated gastrointestinal disorders. With a total of 2 patents, her work focuses on optimizing therapeutic efficacy and predicting patient tolerance to specific medications.

Latest Patents

One of her latest patents is titled "Non-thiopurine methyltransferase related effects in 6-mercaptopurine therapy." This invention provides methods for predicting tolerance associated with 6-mercaptopurine drug treatment of conditions such as inflammatory bowel disease. The patent outlines methods for assessing a patient's risk of adverse drug reactions by genotyping specific genes, including xanthine dehydrogenase (XDH), molybdenum cofactor sulfurase (MOCOS), and aldehyde oxidase (AOX). Furthermore, it offers strategies for determining whether a patient should be prescribed an alternative drug based on genetic polymorphisms.

Career Highlights

Melissa A Smith is affiliated with Guy's and St. Thomas' NHS Foundation Trust, where she continues to advance her research and innovations. Her work has been instrumental in enhancing the understanding of drug interactions and patient-specific responses to therapies.

Collaborations

Some of her notable coworkers include Jeremy D Sanderson and Anthony M Marinaki, who contribute to her research endeavors and collaborative projects.

Conclusion

Melissa A Smith's innovative work in pharmacogenomics exemplifies the importance of personalized medicine in improving patient outcomes. Her patents reflect a commitment to advancing healthcare through scientific research and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…